Navigation Links
Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
Date:3/26/2013

CHARLOTTESVILLE, Virginia und CAMBRIDGE, Massachusetts, March 26, 2013 /PRNewswire/ --

DART Therapeutics Inc., ein innovatives Biotechnologie-Unternehmen neuester Art, das sich auf die Entwicklung von Therapien für die Duchenne-Muskeldystrophie (DMD) konzentriert, und Biovista, ein führender Anbieter für die systematische Neupositionierung von Medikamenten, gaben heute bekannt, dass sie eine Forschungskooperation eingegangen sind, um neuartige Kandidaten für die Neupositionierung von Medikamenten für DMD zu identifizieren und zu entwickeln, wobei die Biovista-Technologie "Clinical Outcome Search Space" (COSS) ™ genutzt werden soll. Gemäß der Vereinbarung wird Biovista neuartige Kandidaten für die Neupositionierung identifizieren und die Firma DART Therapeutics wird die Möglichkeit haben, eine bestimmte Anzahl für die weitere Entwicklung auszuwählen. Die Bedingungen der Vereinbarung umfassen eine Vorauszahlung und nachgeschaltete erfolgsabhängige Zahlungen.

"Die Neupositionierung von Medikamenten ist ein wichtiger Ansatz in unserer Gesamtstrategie zur möglichst effizienten Identifikation neuartiger Behandlungsmethoden für DMD", sagte Gene Williams , Chief Executive Officer von DART Therapeutics. "Biovista und die COSS-Technologie sind führend in der systematischen Neupositionierung und gewährleisten uns die breitestmögliche Abdeckung aller Möglichkeiten der Neupositionierung, die wirklich starke Auswirkungen auf Patienten und ihre Familien haben können, die auf eine Behandlung für DMD warten."

"Das Unternehmen DART Therapeutics steht für ein einzigartiges Modell, das den Entwicklungsarm einer großen Interessengruppe von Patienten darstellt. Die Führungsrolle des Unternehmens bei DMD ist eine ausgezeichnete Ergänzung zu unseren eigenen F
'/>"/>

SOURCE Biovista, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... (PRWEB) October 02, 2014 Permian Plastics, ... in the St. Louis, Missouri, area on October 24th, ... become a leading plastic injection molder in the Midwest. ... and is a supplier to many Fortune 500 clients. ... support every step of the way, from concept to ...
(Date:10/2/2014)... The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama's BRAIN (Brain Research through ... to revolutionize our understanding of the human mind ...
(Date:10/2/2014)... octubre de 2014 Laborie Medical Technologies, Inc. ... , ha completado la adquisición de Unisensor AG y ... su sede central sita en Wiesendangen, Suiza, y lleva ... Portsmouth, New Hampshire . Unisensor está especializada en ... resolución para evaluar la presión y valores de pH ...
(Date:10/2/2014)...  NKT Therapeutics today announced that the U.S. ... designation to NKTT120, the company,s lead therapeutic being ... NKTT120 is a humanized monoclonal antibody that specifically ... has been demonstrated to be a key mediator ... cell disease.  Fast Track designation is intended to ...
Breaking Biology Technology:Permian Plastics LLC Celebrates 20 Years As Leading Manufacturer of Plastic Molds 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 4LABORIE adquiere Unisensor AG y Unisensor USA, Inc. 2FDA Grants Fast Track Designation to NKT Therapeutics' NKTT120 for the Treatment of Sickle Cell Disease 2
... Karudapuram, Ph.D. and David Batey Ph.D. , ... , ... real-time quantitative PCR (qPCR) protocol was used on the MJ Research ... Two hydrolysis probes, one labeled with VIC and the other labeled with FAM, ...
... Ph.D.1, Richard Kurtz, Ph.D.2, David Batey, Ph.D.2 , ... Sciences, Stanford University, Stanford, CA , , ... , ... the amoA gene were used to measure the ammonia-oxidizing bacteria (AOB) population in soils maintained ...
... , AquaPure Genomic DNA Isolation Kit , ... DNA (15-ml tube prep), , Method ... 1. Add 1 ml body fluid (e.g., cerebrospinal fluid, plasma, saliva, serum, , ... , tube containing 5 ml cell lysis solution. Pipet up and ...
Cached Biology Technology:Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 2Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 3Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 4Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 5Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 6Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System 7Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 2Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 3Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 4Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 5Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 6Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 7Genomic DNA Isolation From 1 ml of Body Fluid 2
(Date:9/30/2014)... aquatic environment on Earth, but when the climate changes ... the limit. The amount of time needed to adjust ... species cope in the future, reveals a new study ... the scientific journal Proceedings of the Royal Society ... increasing levels of greenhouse gases in the atmosphere. The ...
(Date:9/30/2014)... If you want your doctor to know what goes wrong ... a good idea to know what "normal" actually is. That,s ... issue of the FASEB Journal comes ... complete transcriptomea key set of molecules that can help scientists ... particular time. What,s more, they found never-before-detected gene activity and ...
(Date:9/30/2014)... People who suffer from asthma may think there,s not ... besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the scientific ... Immunology (ACAAI), asthma sufferers can learn lessons about managing ... in the Annals article improved her asthma once she ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... used by bodybuilders could be the key to treating ... new research shows. The amino acid L-tyrosine had ... in laboratory tests on mice, significantly improving symptoms of ... New South Wales (UNSW) found. Trials showed that ...
... The EpiGen Consortium, an international alliance of the ... Sciences of the Agency for Science, Technology and ... Southampton, Medical Research Council Lifecourse Epidemiology Unit, ... announce the creation of a research collaboration with ...
... 22, 2011 /PRNewswire-iReach/ -- Researchers have demonstrated ... Curran eat significantly more fruits and vegetables and get ... 12 months ago.  By participating in the WellSteps ... in nutrition, physical activity, and sleep quality. Employees also ...
Cached Biology News:Hope for muscle wasting disease 2EpiGen announces collaboration with Nestlé 2New Study Shows Impact of Employee Wellness Efforts 2
... FailSafe™ PCR System is the only PCR ... time and every time. It provides accuracy, ... the source or the property of the ... PCR Enzyme Mix, a unique blend of ...
With L-glutamine and potassium bicarbonate. Sterile, Insect cell culture tested...
Mol wt: average mol wt12,360.96 Da by calculation...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
Biology Products: